drugset / Trial / NCT00232141

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

NCT00232141 ↗

Phase 3 Completed 302 enrolled Viatris Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study to determine if pregabalin is more effective than placebo in treating subjects with nerve pain associated with HIV neuropathy.

Timeline

Start
2005-10
Primary completion
2007-11
Completion
2007-11

Outcome

Missed primary endpoint

registry analysis (unspecified test); Pregabalin vs Placebo; p = 0.3914; Mean Difference (Final Values) -0.25 (95% CI -0.83 to 0.32); ANCOVA NCT00232141 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 300 mg —